GlassScriptPhysician profile
Robert Sisk
NPI 1063614089
$46,244.98
in general payments reported to CMS, 2019-2025
26 companies · $1,421 in 2025
The $1,421 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $11K · 2021: $10K · 2022: $5,225 · 2023: $2,770 · 2024: $16K · 2025: $1,421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $4,313 · Honoraria: $1,892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,734.00 |
| Food and Beverage | $4,312.62 |
| Honoraria | $1,892.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $18,705.90 | 2019-2024 | |
| Leica Microsystems INC. | $15,368.22 | 2020-2025 | Surgical Microscopes |
| Astellas Pharma US INC | $3,118.75 | 2023-2025 | Izervay |
| Apellis Pharmaceuticals, INC. | $2,386.06 | 2022-2025 | Syfovre |
| Allergan, INC. | $2,122.24 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $1,267.04 | 2020-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $1,125.26 | 2021-2025 | Vabysmo, Susvimo |
| Alimera Sciences, INC. | $458.32 | 2019-2024 | Yutiq, Iluvien |
| Alcon Vision LLC | $246.89 | 2021-2023 | |
| Abbvie INC. | $188.20 | 2023-2025 | Ozurdex |
| Novartis Pharmaceuticals Corporation | $178.99 | 2019-2021 | |
| Regeneron Pharmaceuticals, INC. | $138.46 | 2025 | Eylea Hd |
| Astellas US LLC | $135.72 | 2024 | Izervay |
| Carl Zeiss Meditec USA, INC. | $135.08 | 2021 | |
| Ani Pharmaceuticals, INC. | $117.57 | 2025 | Purified Cortrophin Gel, Iluvien, Yutiq |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spark Therapeutics, INC. | $115.75 | 2021-2023 | |
| Samsara Vision | $115.38 | 2025 | Implantable Miniature Telescope (Imt By Dr. Isaac Lipshitz) |
| Bausch & Lomb Americas INC. | $93.42 | 2022-2024 | Vyzulta |
| Biotissue Holdings INC. | $57.11 | 2022-2023 | |
| Notal Vision, INC. | $47.36 | 2021 | |
| Biogen, INC. | $35.99 | 2019-2022 | |
| Sandoz INC. | $28.27 | 2025 | Cimerli |
| Horizon Therapeutics Plc | $17.27 | 2023 | Tepezza |
| Oyster Point Pharma, INC. | $17.15 | 2024 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $13.07 | 2021 | |
| Lumibird Medical INC. | $11.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sisk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.